0000904454-21-000228.txt : 20210222
0000904454-21-000228.hdr.sgml : 20210222
20210222182753
ACCESSION NUMBER: 0000904454-21-000228
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210218
FILED AS OF DATE: 20210222
DATE AS OF CHANGE: 20210222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dietz Thomas John
CENTRAL INDEX KEY: 0001574218
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36066
FILM NUMBER: 21662061
MAIL ADDRESS:
STREET 1: C/O TRANSCEPT PHARMACEUTICAL, INC.
STREET 2: 1003 W. CUTTING BLVD, STE 110
CITY: PT. RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001178711
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330960223
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: (617) 807-6600
MAIL ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc
DATE OF NAME CHANGE: 20090130
FORMER COMPANY:
FORMER CONFORMED NAME: NOVACEA INC
DATE OF NAME CHANGE: 20020724
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2021-02-18
0001178711
Paratek Pharmaceuticals, Inc.
PRTK
0001574218
Dietz Thomas John
C/O PARATEK PHARMACEUTICALS, INC.
75 PARK PLAZA, 4TH FLOOR
BOSTON
MA
02116
1
0
0
0
Common Stock
2021-02-18
4
A
0
9000
0
A
30000
D
Stock Option (right to buy)
7.61
2021-02-18
4
A
0
7000
0
A
2031-02-18
Common Stock
7000
7000
D
Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 18, 2021, subject to the Reporting Person's continued service with the Issuer through the vesting date.
The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant.
The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 18, 2021, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.
/s/ William M. Haskel, Attorney-in-Fact for Thomas John Dietz
2021-02-22